 | ||
| Dear Investor, If you feel like you've missed your shot to build real wealth in the market… don't. Because one of the most consistent profit engines in the financial world is still working, right now. It's called the Zacks Rank. It's driven 142 double and triple-digit wins already this year… And it's behind a portfolio strategy that's averaged +23.6% per year for more than 3 decades. That's not hype or cherry-picked data. That's a verifiable fact. This Monday, the Dream Team at Zacks is unleashing that strategy and releasing a brand new batch of picks… And if you're watching this, you can get them too. Make this Monday count,
P.S. They're so confident, they're offering an unprecedented performance guarantee. You'll see it on the video - go here to get all the details now. | ||
 | ||
| ¹ The results listed above are not (or may not be) representative of the performance of all selections made by Zacks Investment Research's newsletter editors and may represent the partial close of a position. This free resource is being sent by Zacks.com. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms of Service". https://www.zacks.com/terms_of_service Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research is not a licensed securities dealer, broker or U.S. investment adviser or investment bank. The Zacks #1 Rank Performance covers the period beginning on January 1, 1988 through June 2, 2025. The performance is the equal weighted performance of a hypothetical portfolio consisting of stocks with a Zacks Rank of #1 that was rebalanced monthly from January 1988 through December 2013 and weekly from 12/31/13 through Monday's open on June 2, 2025. For each stock with a Zacks Rank #1 at the beginning of the month, the total return during the month was calculated as the % change in the price of the stock from the closing price of the prior month to the closing price of the current month plus any dividends received during the month. The monthly individual stock returns were then averaged to determine the portfolio return for the month. For each stock with a Zacks Rank #1 at the beginning of the week, the total return during the week was calculated as the % change in the price of the stock from the opening price for the week to the opening price of the next week plus any dividends received during the week. The weekly individual stock returns were then averaged to determine the portfolio return for the week. If no month-end price or week end open price was available for a stock, it was not included in the portfolio return for the month or the week. The monthly and weekly returns were compounded to arrive at the annual returns. The annualized return is the annual return that, had it been achieved in each year or portion of a year, would have compounded to create the total return over the full time period. These returns are based on the list of Zacks Rank #1 Stocks that was available to clients of Zacks as of the beginning of the month, when returns were calculated monthly, or as of the beginning of the week when returns were calculated weekly. These returns are higher than the returns an investor could achieve investing real money in a portfolio of Zacks Rank #1 stocks because the returns of the hypothetical Zacks Rank #1 portfolio exclude a number of costs, including commissions incurred for trading, the average bid ask spread, the price impact of the trading and, prior to 2013, in those months when the end of the month fell on Friday, Saturday or Sunday, the overnight return from the month end close to the open on the next trading day. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance_disclosure for information about the performance numbers displayed above. Zacks Emails Zacks Investment Research |
Joby Deal Gives Blade New Direction, But Stock Lacks Lift
Written by Chris Markoch. Published 8/6/2025.
Key Points
- Blade Air Mobility will sell its passenger division to Joby Aviation, pivoting to a pure-play medical logistics model.
- The $125 million stock-based deal is set to close in the first half of 2026, introducing potential valuation and timeline risk.
- Investors may want to wait for deal clarity before getting involved with BLDE stock.
It’s been quite the week for Blade Air Mobility Inc. (NASDAQ: BLDE). On August 4, Blade and Joby Aviation Inc. (NYSE: JOBY) announced the sale of Blade’s passenger mobility business to Joby for up to $125 million. That sent BLDE stock soaring 30%. Blade will become a pure-play medical logistics company and change its name to Strata Critical Medical.
However, the stock has given up most of those gains after the company delivered a mixed earnings report. Although it beat on the top line, it delivered negative earnings per share of five cents, which was a penny worse than the negative four cents analysts were expecting.
The earnings report is a reminder that Blade has tremendous potential and serves a critical niche among business services stocks. However, the company is not yet profitable, and it may take some time for it to realize the economic benefits from the Joby deal.
The Passenger Division Sale May Be Addition by Subtraction
Blade Air Mobility operates as two divisions: Medical and Blade Passenger. The medical division is primarily comprised of its MediMobility Organ Transport business. The company is the largest dedicated air transporter of human organs for transplant in the United States.
As of this quarter’s earnings, nearly 60% of the company’s revenue and 84% of its EBITDA (earnings before interest, taxes, depreciation, and amortization) came from its medical division. In the quarter, Blade posted 18% year-over-year (YOY) revenue growth from the medical division. This contrasts with the combined 8% YOY revenue decline in its short-distance and Jets business in the passenger division.
Blade Anticipates a Leaner, Profitable Business
The company’s earnings report was heavily focused on the impact of the Joby deal on Blade’s business. Management was bullish on the outlook, citing an expectation for “continued attractive organic growth over the coming years.” The company also said it plans to pursue strategic acquisitions with the expected $200 million of cash on hand, pro forma for selling its passenger business.
In short, investors can expect a leaner company with more predictable cash flows, focused on non-emergency medical transport (NEMT), organ transfer, and time-critical healthcare logistics.
As the company’s quarterly results bear out, this is a less volatile space compared to urban air travel.
The Risk Is in the Details
The sale of Blade’s passenger business to Joby is for “up to” $125 million. That’s because the sale will be paid entirely in Joby stock. On the company’s earnings call, Blade’s management didn’t express concern over Joby’s ability to deliver.
That said, a deal based on a stock-based structure opens the possibility that Joby’s share price could impact Blade's final payout.
This risk is somewhat amplified because Blade's chief executive officer (CEO), Rob Wiesenthal, remarked that the deal will close in the first half of 2026.
That’s not an unusual timeline for a deal involving regulatory approvals. However, it does extend the runway for stock price volatility, particularly for a pre-revenue aviation startup like Joby.
BLDE Stock May Need Time to Take Off
What Blade might be (i.e., a profitable, asset-light medical mobility company) is enticing. The company estimates the organ logistics market to be an addressable market worth about $1 billion, of which Blade already controls about 30%.
But that’s not where the company is today. It’s also not what attracted some initial investors to the company. Those investors were attracted to the opportunity in air mobility. While the resulting company may offer stability and near-term profits, the upside will likely be capped.
Until its passenger business is sold, investors should expect BLDE stock to reflect cautious optimism at best. However, it's likely to be choppy as traders look for opportunities for short-term gains.
Investors with a lower risk tolerance may want to wait until the deal is closer to completion before deciding on BLDE stock. However, risk-tolerant investors may want to start building a position and scale in as the final details of the deal emerge.
This email content is a sponsored email sent on behalf of Zacks, a third-party advertiser of InsiderTrades.com and MarketBeat.
If you need help with your subscription, please feel free to email MarketBeat's U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
Copyright 2006-2025 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place #620, Sioux Falls, S.D. 57103-7078. USA..
0 Response to "44 winning trades in the past 12 months alone"
Post a Comment